Role of TTV During First-line Immunotherapy Treatment in Patients With Renal Cell Carcinoma

Summary

The aim of this project is to descriptively explore the trend of torquetenovirus viral load TTV during therapy with immune checkpoint inhibitor ICI in these patients, to evaluate a possible role of this virus as a biomarker of response.

Eligibility

Inclusion Criteria:

* Patients over 18 years of age;
* Histological diagnosis of clear cell renal cell carcinoma;
* Evidence of advanced or metastatic disease;
* Patients diagnosed with metastatic clear cell renal cell carcinoma about to start first-line immunotherapy (ICI + ICI or ICI + TKI);
* Patients able to comply with the study procedures.
* Patients who give written informed consent personally or through a witness (study participation and data processing), before any study-specific procedure is started.

Exclusion Criteria:

* Previous neoplasms;
* Previous antineoplastic treatments;
* Previous steroid treatments;
* Active viral infections (e.g., HCV, HIV, etc.);
* Lack of autonomy in adhering to study procedures.

Conditions2

Browse More Trials